Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom
dimensions. The negative symptom dimension, with its protean cognitive manifestations,
responds poorly to treatment, which can be a particular challenge in countries where
clozapine therapy is not available. Preliminary data indicates that minocycline may be
beneficial adjunct in the treatment of schizophrenia: positive, negative, and cognitive
symptoms. Persons with schizophrenia or schizoaffective disorder and recent onset
schizophrenic episode or recent relapse who are prescribed minocycline in addition to
standard antipsychotic medication will show greater symptom reduction, as measured by the
Positive and Negative Syndrome Scale (PANSS) total score.